Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.

Oncotarget - 12 Apr 2016

Buckley Niamh E, Haddock Paula, De Matos Simoes Ricardo, Parkes Eileen, Irwin Gareth, Emmert-Streib Frank, McQuaid Stephen, Kennedy Richard, Mullan Paul

Abstract excerpt

Triple negative (TNBCs) and the closely related Basal-like (BLBCs) breast cancers are a loosely defined collection of cancers with poor clinical outcomes. Both show strong similarities with BRCA1-mutant breast cancers and BRCA1 dysfunction, or 'BRCAness', is observed in a large proportion of sporadic BLBCs. BRCA1 expression and function has been shown in vitro to modulate responses to radiation and chemotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Kaplan-Meier Estimate

Share to NF-kappa B

Share to Outcome Assessment, Health Care

Share to Reactive Oxygen Species

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26943587
DOI: 10.18632/oncotarget.7865
PMCID: PMC4991425

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.PMID 26943587Read ↗

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.Semantic proximity Read ↗

Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.Semantic proximity Read ↗

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.Semantic proximity Read ↗

Exploring Molecular Pathways of Triple-Negative Breast CancerSemantic proximity Read ↗

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapySemantic proximity Read ↗

Triple-negative breast cancer: current state of the art.Semantic proximity Read ↗

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancerSemantic proximity Read ↗

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.Semantic proximity Read ↗

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerSemantic proximity Read ↗

Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancerSemantic proximity Read ↗

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.Semantic proximity Read ↗

BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.